Brokerages Set Voyager Therapeutics, Inc. (NASDAQ:VYGR) Price Target at $17.43

Voyager Therapeutics, Inc. (NASDAQ:VYGR) has been assigned a consensus rating of “Buy” from the eight research firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.43.

VYGR has been the subject of several recent analyst reports. Leerink Partnrs raised shares of Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Wedbush cut their price target on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Voyager Therapeutics in a research note on Thursday, October 24th. StockNews.com lowered shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. Finally, Leerink Partners began coverage on shares of Voyager Therapeutics in a research note on Wednesday, October 16th. They set an “outperform” rating and a $15.00 price target on the stock.

Voyager Therapeutics Stock Down 3.3 %

Shares of VYGR stock opened at $6.84 on Monday. The stock has a market capitalization of $372.05 million, a PE ratio of -138.60 and a beta of 0.91. The firm has a 50 day moving average of $6.56 and a two-hundred day moving average of $7.58. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.20. The business had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same period in the previous year, the company earned ($0.51) EPS. Analysts expect that Voyager Therapeutics will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total value of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares in the company, valued at approximately $500,525.82. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.53% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in VYGR. Allspring Global Investments Holdings LLC increased its stake in shares of Voyager Therapeutics by 2.1% during the first quarter. Allspring Global Investments Holdings LLC now owns 99,306 shares of the company’s stock worth $925,000 after acquiring an additional 2,030 shares during the period. Commonwealth Equity Services LLC acquired a new position in shares of Voyager Therapeutics during the first quarter worth about $530,000. BNP Paribas Financial Markets boosted its holdings in Voyager Therapeutics by 198.6% during the first quarter. BNP Paribas Financial Markets now owns 48,769 shares of the company’s stock worth $454,000 after buying an additional 32,437 shares in the last quarter. Empowered Funds LLC boosted its holdings in Voyager Therapeutics by 8.2% during the first quarter. Empowered Funds LLC now owns 39,471 shares of the company’s stock worth $367,000 after buying an additional 2,975 shares in the last quarter. Finally, ClariVest Asset Management LLC boosted its holdings in Voyager Therapeutics by 59.3% during the first quarter. ClariVest Asset Management LLC now owns 100,123 shares of the company’s stock worth $932,000 after buying an additional 37,275 shares in the last quarter. 48.03% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.